CN105963239A - 可促进皮肤再生的乳液 - Google Patents
可促进皮肤再生的乳液 Download PDFInfo
- Publication number
- CN105963239A CN105963239A CN201610537353.4A CN201610537353A CN105963239A CN 105963239 A CN105963239 A CN 105963239A CN 201610537353 A CN201610537353 A CN 201610537353A CN 105963239 A CN105963239 A CN 105963239A
- Authority
- CN
- China
- Prior art keywords
- emulsion
- skin
- stem cell
- skin regeneration
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 31
- 230000001737 promoting effect Effects 0.000 title claims abstract description 15
- 210000000130 stem cell Anatomy 0.000 claims abstract description 50
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 230000036560 skin regeneration Effects 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims abstract description 18
- 239000003755 preservative agent Substances 0.000 claims abstract description 15
- 230000002335 preservative effect Effects 0.000 claims abstract description 15
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 13
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 12
- 229960000458 allantoin Drugs 0.000 claims abstract description 12
- -1 penetrant Substances 0.000 claims abstract description 11
- 239000002131 composite material Substances 0.000 claims abstract description 10
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims description 22
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 239000007864 aqueous solution Substances 0.000 claims description 18
- 239000002994 raw material Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 12
- 210000002706 plastid Anatomy 0.000 claims description 12
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 10
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 10
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 10
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 10
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 10
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 10
- 229920002643 polyglutamic acid Polymers 0.000 claims description 10
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 10
- 229940035936 ubiquinone Drugs 0.000 claims description 10
- 239000008346 aqueous phase Substances 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 9
- 239000012071 phase Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 229940032094 squalane Drugs 0.000 claims description 9
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 8
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 8
- 229920002498 Beta-glucan Polymers 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 239000011630 iodine Substances 0.000 claims description 8
- KRPAJLYSLFNDOA-UHFFFAOYSA-N mephenesin carbamate Chemical compound CC1=CC=CC=C1OCC(O)COC(N)=O KRPAJLYSLFNDOA-UHFFFAOYSA-N 0.000 claims description 8
- 229950006838 mephenesin carbamate Drugs 0.000 claims description 8
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 8
- ZOMATQMEHRJKLO-UHFFFAOYSA-N 1h-imidazol-2-ylmethanol Chemical compound OCC1=NC=CN1 ZOMATQMEHRJKLO-UHFFFAOYSA-N 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 229930003799 tocopherol Natural products 0.000 claims description 6
- 229960001295 tocopherol Drugs 0.000 claims description 6
- 239000011732 tocopherol Substances 0.000 claims description 6
- 235000010384 tocopherol Nutrition 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000012531 culture fluid Substances 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 230000000149 penetrating effect Effects 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- ILYCWAKSDCYMBB-OPCMSESCSA-N dihydrotachysterol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1/C[C@@H](O)CC[C@@H]1C ILYCWAKSDCYMBB-OPCMSESCSA-N 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 231100000245 skin permeability Toxicity 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 239000002771 cell marker Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 abstract description 42
- 230000032683 aging Effects 0.000 abstract description 7
- 210000002615 epidermis Anatomy 0.000 abstract description 7
- 230000003020 moisturizing effect Effects 0.000 abstract description 4
- 210000002514 epidermal stem cell Anatomy 0.000 abstract description 3
- 210000003954 umbilical cord Anatomy 0.000 abstract description 3
- 208000028990 Skin injury Diseases 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 210000004207 dermis Anatomy 0.000 abstract 1
- 210000004700 fetal blood Anatomy 0.000 abstract 1
- 239000003906 humectant Substances 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- BVTHRGZMQHOCOL-UHFFFAOYSA-N OCC(O)(C1(NC(=O)NCNC(=O)NC2(CO)NC(=O)NC2=O)NC(=O)NC1=O)CO Chemical compound OCC(O)(C1(NC(=O)NCNC(=O)NC2(CO)NC(=O)NC2=O)NC(=O)NC1=O)CO BVTHRGZMQHOCOL-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000005059 dormancy Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 235000013557 nattō Nutrition 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035806 respiratory chain Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001835 salubrious effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036558 skin tension Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开一种可促进皮肤再生的乳液，由保湿剂、渗透剂、防腐剂、乳化剂、干细胞复合因子、细胞脂质体以及尿囊素制作，所采用的成分安全，与皮肤的亲和度高，具有滋润保湿的功能。用人脐带或脐血间充质干细胞分泌的被细胞脂质体裹的干细胞因子用于皮肤的再生。在脂质体的包裹下，干细胞因子能够深层渗透到皮肤干细胞所在的表皮基底层以及真皮层，增加皮肤干细胞中的干细胞因子浓度，激活休眠以及衰老的表皮干细胞以及真皮间充质干细胞，启动皮肤自我修复机制，逆转衰老过程，促进皮肤损伤愈合。
Description
技术领域
本发明涉及皮肤护理的技术领域，尤其涉及一种可促进皮肤再生的乳液。
背景技术
皮肤衰老是由自然因素或非自然因素造成的皮肤组织萎缩以及生理功能下降现象。皮肤组织减少：皮肤的厚度随着年龄的增加而有明显改变。人的表皮20岁时最厚，以后逐渐变薄，到老年期颗粒层可萎缩至消失，棘细胞生存期缩短。表皮细胞核分裂增加，故黑色素亦增多，以致老年人的肤色多为棕黑色。由于老化细胞附着于表皮角质层，使皮肤表面变硬，失去光泽。真皮在30岁时最厚，以后渐变薄并伴有萎缩。皮下脂肪减少，并由于弹力纤维与胶原纤维发生变化而渐失皮肤弹性和张力，更进一步导致皮肤松弛与皱纹产生。生理功能低下：皮脂腺、汗腺功能下降，汗液与皮脂分泌减少，皮肤逐渐失去昔日光泽而变得干燥。血液循环功能减退，难以补充皮肤组织生命活动必要的营养，因此老年人皮肤伤口难愈合。皮肤衰老直接影响人体健康。
皮肤组织的修复是对抗皮肤衰老以及损伤修复的主要过程。皮肤自然修复的过程，需要通过表皮深层的表皮干细胞以及真皮层的间充质干细胞的功能实现。这些干细胞通过自我更新以及分化成皮肤各层组织细胞，逐步补充受损皮肤组织中的细胞以及纤维蛋白。这一过程需要皮肤内环境中的干细胞因子对干细胞进行刺激。正常皮肤内环境中的干细胞因子含量，只能够维持皮肤干细胞以较低的速率进行自我更新以及分化，而增加内环境中的干细胞因子浓度，则可以激活休眠以及衰老的干细胞，使得更多干细胞参与皮肤组织修复进程。但是如何使得体外的干细胞因子达到深层皮肤组织，而不会被表皮浅表各层阻挡隔离，是目前一大技术难题。另外，目前市面上类似的抗衰老产品主要是通过补充透明质酸以及氨基酸等细胞营养成分，从而填充因衰老而缺损的细胞外基质以及提供细胞代谢消耗所需，但是不能激活皮肤自我修复程序，实现真正的逆转衰老。
发明内容
针对上述技术中存在的不足之处，本发明提供一种成份安全、与皮肤亲和力高的可促进皮肤再生的乳液。
为了达到上述目的，本发明一种可促进皮肤再生的乳液，包括
保湿剂0.02~0.2份；
渗透剂2~8份；
防腐剂0.06~0.1份；
乳化剂1~3份；
以及活性成分，其中活性成分包括：
干细胞复合因子0.01~10份；
细胞脂质体0.005~0.1份；
尿囊素0.01~0.03份。
其中，所述活性成分还包括生育酚0.01~0.3份、泛醌0.01~0.2份以及β-葡聚糖0.01~0.3份。
其中，所述保湿剂包括透明质酸钠0.01~0.1份以及聚谷氨酸0.01~0.1份。
其中，所述渗透剂包括角鲨烷1~5份以及肉豆蔻酸异丙酯1~3份。
其中，所述防腐剂包括双羟甲基咪唑烷基脲0.03~0.05份以及碘丙炔醇丁基氨甲酸酯0.03~0.05份。
其中，所述乳化剂为鲸蜡基PEG/PPG-10/1聚二甲基硅氧烷1~3份。
其中，该乳液还包括去离子水1~10份以及甘油1~10份。
本发明一种可促进皮肤再生的乳液的制备方法，包括以下过程
S1、干细胞因子的提取：取人脐带组织，按照细胞标记物分离间充质干细胞，置于细胞培养基，放入培养箱中，恒温恒湿持续传代培养4到5代，将细胞连培养基置于低氧培养箱中，促进细胞因子的分泌，然后过滤细胞，保留上清液，得到复合干细胞因子培养液；
S2、添加细胞脂质体：再往复合干细胞因子培养液加入细胞脂质体，使得干细胞因子被包裹在脂质体中，增加干细胞因子皮肤渗透力，最终形成干细胞因子液A液；
S3、基底乳液的调配：将油相原料置于反应锅内加热搅拌均匀；将水相原料充分溶解后加入反应锅内，加入乳化剂，使油相原料与水相原料充分乳化混合，形成乳液B液；
S4、A液与B液混合：将A液与B液置于同一反应锅内，充分搅拌混合，搅拌过程中加入防腐剂，在搅拌均匀后，通过紫外线消毒灭菌，灌装成品。
其中，所述油相原料包括：角鲨烷, 肉豆蔻酸异丙酯, 鲸蜡基 PEG/PPG-10/1 聚二甲基硅氧烷；水相原料包括：甘油、生育酚水溶液，泛醌水溶液，尿囊素水溶液，β-葡聚糖水溶液，透明质酸钠水溶液，聚谷氨酸水溶液。
其中，在S3的过程中运用的乳化剂为鲸蜡基PEG/PPG-10/1聚二甲基硅氧烷，在S4的过程中运用的防腐剂为双羟甲基咪唑烷基脲以及碘丙炔醇丁基氨甲酸酯。
本发明的有益效果是：
与现有技术相比，本发明的可促进皮肤再生的乳液，由保湿剂、渗透剂、防腐剂、乳化剂、干细胞复合因子、细胞脂质体以及尿囊素制作，所采用的成分安全，与皮肤的亲和度高，具有滋润保湿的功能。用人脐带间充质干细胞分泌的细胞脂质体裹干细胞因子。在脂质体的包裹下，干细胞因子能够深层渗透到皮肤干细胞所在的表皮基底层以及真皮层，增加皮肤干细胞中的干细胞因子浓度，激活休眠以及衰老的表皮干细胞以及真皮间充质干细胞，启动皮肤自我修复机制，逆转衰老过程，促进皮肤损伤愈合。
附图说明
图1为本发明可促进皮肤再生的乳液的制备方法的流程图。
具体实施方式
为了更清楚地表述本发明，下面结合附图对本发明作进一步地描述。
本发明公开一种可促进皮肤再生的乳液，包括
透明质酸钠0.01~0.1份；
聚谷氨酸0.01~0.1份；
角鲨烷1~5份；
肉豆蔻酸异丙酯1~3份；
双羟甲基咪唑烷基脲0.03~0.05份；
碘丙炔醇丁基氨甲酸酯0.03~0.05份；
鲸蜡基PEG/PPG-10/1聚二甲基硅氧烷1~3份；
以及活性成分，其中活性成分包括：
干细胞复合因子0.01~10份；
细胞脂质体0.005~0.1份；
尿囊素0.01~0.03份；
泛醌0.01~0.2份；
β-葡聚糖0.01~0.3份；
去离子水1~10份以及甘油1~10份。
具体操作过程中的成分配方为：
透明质酸钠0.01份；
聚谷氨酸0.01份；
角鲨烷3份；
肉豆蔻酸异丙酯1份；
双羟甲基咪唑烷基脲0.03份；
碘丙炔醇丁基氨甲酸酯0.03份；
鲸蜡基PEG/PPG-10/1聚二甲基硅氧烷1份；
以及活性成分，其中活性成分包括：
干细胞复合因子0.01份；
细胞脂质体0.005份；
尿囊素0.01份；
泛醌0.01份；
β-葡聚糖0.01份；
去离子水8份以及甘油3份。
该配方制成的乳液，质地柔和，偏水性，适合用于多数人群皮肤状况。
具体成分说明：
生育酚：即维生素E，能维持生殖器官正常机能，对机体的代谢有良好的影响，能促进卵巢功能， 促进卵泡的成熟，使黄体增大，并可抑制孕酮在全内的氧化，从而增加孕酮的作用。近年来，维生素E又被广泛用于抗衰老方面，它可消除脂褐素在细胞中的沉积，改善细胞的正常功能，减慢组织细胞的衰老过程。
干细胞复合因子：来源于人脐带间充质干细胞分泌的囊泡，为超过200种多肽的混合物，具有激活皮肤沉睡衰老干细胞功能，促进皮肤干细胞自我更新与分化，补充皮肤组织所需要的细胞及细胞外基质。
泛醌：又称辅酶Q，是一种存在于自然界的脂溶性醌类化合物，其结构与维生素K、维生素E相似。泛醌存在于多数真核细胞中，尤其是线粒体。它是呼吸链组分之一，其在线粒体内膜上的含量远远高于呼吸链其他组分的含量。还能将线粒体制造能量过程中产生的活性氧清除。
尿囊素：在多种生物中是尿酸的分解代谢产物。尿囊素具有促进细胞生长，加快伤口愈合，软化角质蛋白等生理功能，是皮肤创伤的良好愈合剂和抗溃疡药剂。可用作缓解和治疗皮肤干燥症、鳞屑性肤疾患、皮肤溃疡，对痤疮有较好疗效。由于尿囊素是一种两性化合物，能结合多种物质形成复盐， 具有避光、杀菌防腐、止痛、抗氧化作用，能使皮肤保持水份，滋润和柔软。
β-葡聚糖：其活性结构是由葡萄糖单位组成的多聚糖，它们大多数通过β-1,3结合，这是葡萄糖链连接的方式。它能够活化巨噬细胞、嗜中性白血球等，因此能提高白细胞素、细胞分裂素和特殊抗体的含量，全面刺激机体的免疫系统。
角鲨烷：是从深海鲨鱼肝脏中提取的角鲨烯，经氢化制得一种性能优异的烃类油脂，故又名深海鲨鱼肝油。角鲨烷是少有的化学稳定性高，使用感极佳的动物油脂，对皮肤有较好的亲和性，不会引起过敏和刺激，并能加速配方中其他活性成分向皮肤中渗透；具有较低的极性和中等的铺展性，且纯净、无色、无异味；还可抑制霉菌的生长。
肉豆蔻酸异丙酯：广泛应用于化妆品中，可以起到保湿和滋润皮肤的作用，皮肤对本品的吸收较好，能在皮层内与毛囊有效接触，渗入皮层深处，并将化妆品中的活性组分带入，充分发挥有效成分的作用。
透明质酸钠：是人皮肤表皮及真皮的主要基质成分之一，其生理功能是能使水分进入细胞间隙，并与蛋白质结合而形成蛋白凝胶，保持皮肤的湿润、清爽，使皮肤更富有弹性。
聚谷氨酸：又称纳豆胶、多聚谷氨酸，它是一种水溶性，生物降解，不含毒性，使用微生物发酵法制得的生物高分子。聚谷氨酸是一种有粘性的物质，在“纳豆” ——发酵豆中被首次发现。其保湿锁水功效是透明质酸的500倍。
双（羟甲基）咪唑烷基脲：通常用做化妆品防腐剂。几乎能与化妆品中所有组份互配。适用于化妆品的pH值范围为4-9。
碘丙炔醇丁基氨甲酸酯：是一种新型化妆品用防腐剂，具有很好的抑菌效果，并在表面活性剂、乳化剂、极性溶剂中有较好的溶解性，因此被广泛应用于驻留类和淋洗类化妆品配方中，常与双(羟甲基)咪唑烷基脲、乙内酰脲等其他防腐剂配合使用。
本发明一种可促进皮肤再生的乳液的制备方法，包括以下过程：
S1、干细胞因子的提取：脐带胶质组织中分离间充质干细胞，该种细胞表达特异性标志物CD73、CD90、CD105，不表达标志物CD14、CD45，可用特异性荧光标志物抗体检测上述标志物表达情况。将间充质干细胞接种于培养基中，培养细胞并且分离提纯干细胞因子的步骤包括：将间充质干细胞以3×106/ml~5×106/ml的密度接种于IMDM培养基；在37℃、5%CO2、饱和湿度下培养；通过平行摇动培养基3到5次以诱导细胞贴壁，72小时后全量换液，去除非贴壁细胞，添加新鲜培IMDM养基；以及当贴壁细胞的融合度为85%~95%时，进行细胞传代，传到第4至6代时，收集间充质干细胞培养基上清液，以2000转/分钟的转速离心10分钟，以分离上清中的间充质干细胞（离心后沉淀）以及干细胞因子（在上清液中），再通过2000da~3000da的透析袋或超滤管过滤离心后的上清液，过滤培养基中诸如组胺、前列腺素、血小板活化因子等过敏成分，同时保留间充质干细胞分泌因子。再将滤液转移到试管中，4℃储存备用；
S2、添加细胞脂质体：再往储存的复合干细胞因子培养液加入细胞脂质体，使得干细胞因子被包裹在脂质体中，增加干细胞因子皮肤渗透力，最终形成干细胞因子液A液；
S3、基底乳液的调配：将油相原料置于反应锅内加热搅拌均匀；将水相原料充分溶解后加入反应锅内，加入乳化剂，使油相原料与水相原料充分乳化混合，形成乳液B液；
S4、A液与B液混合：将A液与B液置于同一反应锅内，充分搅拌混合，搅拌过程中加入防腐剂，在搅拌均匀后，通过紫外线消毒灭菌，灌装成品。
在本实施例中，所述油相原料包括 ：角鲨烷, 肉豆蔻酸异丙酯, 鲸蜡基 PEG/PPG-10/1 聚二甲基硅氧烷。水相原料包括：生育酚水溶液，泛醌水溶液， 尿囊素水溶液，β-葡聚糖水溶液，透明质酸钠水溶液，聚谷氨酸水溶液。
在本实施例中，在S3的过程中运用的乳化剂为鲸蜡基PEG/PPG-10/1聚二甲基硅氧烷，在S4的过程中运用的防腐剂为双羟甲基咪唑烷基脲以及碘丙炔醇丁基氨甲酸酯。
以上公开的仅为本发明的几个具体实施例，但是本发明并非局限于此，任何本领域的技术人员能思之的变化都应落入本发明的保护范围。
Claims (10)
1.一种可促进皮肤再生的乳液，其特征在于，包括
保湿剂0.02~0.2份；
渗透剂2~8份；
防腐剂0.06~0.1份；
乳化剂1~3份；
以及活性成分，其中活性成分包括：
干细胞复合因子0.01~10份；
细胞脂质体0.005~0.1份；
尿囊素0.01~0.03份。
2.根据权利要求1所述的可促进皮肤再生的乳液，其特征在于，所述活性成分还包括生育酚0.01~0.3份、泛醌0.01~0.2份以及β-葡聚糖0.01~0.3份。
3.根据权利要求2所述的可促进皮肤再生的乳液，其特征在于，所述保湿剂包括透明质酸钠0.01~0.1份以及聚谷氨酸0.01~0.1份。
4.根据权利要求1所述的可促进皮肤再生的乳液，其特征在于，所述渗透剂包括角鲨烷1~5份以及肉豆蔻酸异丙酯1~3份。
5.根据权利要求1所述的可促进皮肤再生的乳液，其特征在于，所述防腐剂包括双羟甲基咪唑烷基脲0.03~0.05份以及碘丙炔醇丁基氨甲酸酯0.03~0.05份。
6.根据权利要求1所述的可促进皮肤再生的乳液，其特征在于，所述乳化剂为鲸蜡基PEG/PPG-10/1聚二甲基硅氧烷1~3份。
7.根据权利要求1所述的可促进皮肤再生的乳液，其特征在于，该乳液还包括去离子水1~10份以及甘油1~10份。
8.一种可促进皮肤再生的乳液的制备方法，其特征在于，包括以下过程
S1、干细胞因子的提取：取人脐带组织，按照细胞标记物分离间充质干细胞，置于细胞培养基，放入培养箱中，恒温恒湿持续传代培养4到5代，将细胞连培养基置于低氧培养箱中，促进细胞因子的分泌，然后过滤细胞，保留上清液，得到复合干细胞因子培养液；
S2、添加细胞脂质体：再往复合干细胞因子培养液加入细胞脂质体，使得干细胞因子被包裹在脂质体中，增加干细胞因子皮肤渗透力，最终形成干细胞因子液A液；
S3、基底乳液的调配：将油相原料置于反应锅内加热搅拌均匀；将水相原料充分溶解后加入反应锅内，加入乳化剂，使油相原料与水相原料充分乳化混合，形成乳液B液；
S4、A液与B液混合：将A液与B液置于同一反应锅内，充分搅拌混合，搅拌过程中加入防腐剂，在搅拌均匀后，通过紫外线消毒灭菌，灌装成品。
9.根据权利要求8所述的可促进皮肤再生的乳液的制备方法，其特征在于，所述油相原料包括：角鲨烷, 肉豆蔻酸异丙酯, 鲸蜡基 PEG/PPG-10/1 聚二甲基硅氧烷；水相原料包括：甘油、生育酚水溶液，泛醌水溶液，尿囊素水溶液，β-葡聚糖水溶液，透明质酸钠水溶液，聚谷氨酸水溶液。
10.根据权利要求8所述的可促进皮肤再生的乳液的制备方法，其特征在于，在S3的过程中运用的乳化剂为鲸蜡基PEG/PPG-10/1聚二甲基硅氧烷，在S4的过程中运用的防腐剂为双羟甲基咪唑烷基脲以及碘丙炔醇丁基氨甲酸酯。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610537353.4A CN105963239A (zh) | 2016-07-11 | 2016-07-11 | 可促进皮肤再生的乳液 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610537353.4A CN105963239A (zh) | 2016-07-11 | 2016-07-11 | 可促进皮肤再生的乳液 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105963239A true CN105963239A (zh) | 2016-09-28 |
Family
ID=56952256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610537353.4A Pending CN105963239A (zh) | 2016-07-11 | 2016-07-11 | 可促进皮肤再生的乳液 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105963239A (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106491486A (zh) * | 2016-10-26 | 2017-03-15 | 武汉汉密顿生物科技股份有限公司 | 一种含脐带血干细胞衍生液的脂质体混悬液及其制备方法和在化妆品中的应用 |
| CN107029219A (zh) * | 2017-06-04 | 2017-08-11 | 重庆华邦医美科技有限公司 | 一种促进皮肤组织再生的药膏 |
| CN109056333A (zh) * | 2018-09-07 | 2018-12-21 | 浙江新胜油脂科技有限公司 | 一种涤纶纺丝用油剂组合物 |
| CN109394563A (zh) * | 2018-11-06 | 2019-03-01 | 福建省海西细胞生物工程有限公司 | 一种干细胞培养基脂质体的制备方法及在护肤品中的应用 |
| CN110623847A (zh) * | 2019-09-30 | 2019-12-31 | 陕西中鸿科瑞再生医学研究院有限公司 | 一种用类人体纳米微囊透皮缓释技术制备皮损修复冻干粉的方法 |
| CN113304096A (zh) * | 2020-03-30 | 2021-08-27 | 大树医疗美容科技(广州)有限公司 | 一种提供人体皮肤细胞组织营养液配方及其制备方法 |
-
2016
- 2016-07-11 CN CN201610537353.4A patent/CN105963239A/zh active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106491486A (zh) * | 2016-10-26 | 2017-03-15 | 武汉汉密顿生物科技股份有限公司 | 一种含脐带血干细胞衍生液的脂质体混悬液及其制备方法和在化妆品中的应用 |
| CN107029219A (zh) * | 2017-06-04 | 2017-08-11 | 重庆华邦医美科技有限公司 | 一种促进皮肤组织再生的药膏 |
| CN109056333A (zh) * | 2018-09-07 | 2018-12-21 | 浙江新胜油脂科技有限公司 | 一种涤纶纺丝用油剂组合物 |
| CN109394563A (zh) * | 2018-11-06 | 2019-03-01 | 福建省海西细胞生物工程有限公司 | 一种干细胞培养基脂质体的制备方法及在护肤品中的应用 |
| CN110623847A (zh) * | 2019-09-30 | 2019-12-31 | 陕西中鸿科瑞再生医学研究院有限公司 | 一种用类人体纳米微囊透皮缓释技术制备皮损修复冻干粉的方法 |
| CN113304096A (zh) * | 2020-03-30 | 2021-08-27 | 大树医疗美容科技(广州)有限公司 | 一种提供人体皮肤细胞组织营养液配方及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105963239A (zh) | 可促进皮肤再生的乳液 | |
| KR101678621B1 (ko) | 스피큘을 포함하는 피부관리용 화장품 조성물 및 이의 제조방법 | |
| DK2510980T3 (en) | Method of dermocosmetic treatment of skin by application of NGF-containing compositions | |
| CN106137906A (zh) | 一种植物精粹修护面膜精华液 | |
| WO2014044808A2 (en) | Fast-penetration cosmetic dermal filler for topical application | |
| CN108653013A (zh) | 一种植物保湿水润晒后修复霜及其制备方法 | |
| KR102613845B1 (ko) | 천연물 유래의 피부개선용 화장조성물 | |
| CN115813774B (zh) | 具有美白效果的水油双层精粹组合物及其制备方法与应用 | |
| CN109260035A (zh) | 一种含富勒烯的美白抗衰组合物及其制备方法 | |
| CN108653006A (zh) | 一种植物保湿全效眼霜及其制备方法 | |
| JP2020100663A (ja) | 有効成分としてミントビネガーを含有する化粧料組成物 | |
| CN104586740A (zh) | 一种保湿美容面膜及其制备方法 | |
| CN108542851A (zh) | 一种中药保湿防皲裂护手霜及其制备方法 | |
| WO2015163838A1 (en) | Skin treatment formulations | |
| KR102611907B1 (ko) | 스피큘 추출물을 함유한 기능성 화장품 조성물 및 이의 제조 방법 | |
| RU2328324C2 (ru) | Способ устранения косметических недостатков и предотвращения возрастных изменений кожи | |
| KR101981590B1 (ko) | 삼백초 발효 추출물을 함유하는 보습용 화장료 조성물 | |
| KR20010090063A (ko) | 머드(Mud) 팩의 조성물 | |
| CN103356475B (zh) | 祛皱嫩肤乳液 | |
| CN108888573B (zh) | 舒敏保湿滋润霜及其制备方法 | |
| CN112137927A (zh) | 高渗透、重现光感初生肌的纤连蛋白精华乳及其制备方法 | |
| KR20090003828A (ko) | 탈모방지 및 발모 조성물을 함유하는 헤어토닉 | |
| CN118021691B (zh) | 一种深度补水的化妆品组合物及其制备方法 | |
| CN112641685A (zh) | 一种保湿促循环精华液及其制备方法 | |
| KR102691494B1 (ko) | 과일 착즙 잔류물을 이용한 워시오프 타입 팩용 화장료 조성물 및 이의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160928 |